Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bicara Therapeutics Inc.
Report date September 16, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectEight Roads Ventures India Healthcare IV, L.P. | 54,092 |
Reported balance
After 2024-09-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-09-16 · Conversion · Acquired 54,092 · Balance 54,092 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectEight Roads Ventures India Healthcare IV, L.P. | 660,977 |
Reported balance
After 2024-09-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-16 · Conversion · Acquired 606,885 · Balance 660,977 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectEight Roads Ventures India Healthcare IV, L.P. | 1,013,853 |
Reported balance
After 2024-09-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-16 · Conversion · Acquired 352,876 · Balance 1,013,853 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectEight Roads Ventures India Healthcare IV, L.P. | 0 |
Reported balance
After 2024-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-16 · Conversion · Disposed 54,092 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectEight Roads Ventures India Healthcare IV, L.P. | 0 |
Reported balance
After 2024-09-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-16 · Conversion · Disposed 606,885 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectEight Roads Ventures India Healthcare IV, L.P. | 0 |
Reported balance
After 2024-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-09-16 · Conversion · Disposed 352,876 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Cogent Biosciences, Inc.
Report date April 03, 2018 · Filed April 05, 2018
Section 16 reporting ended · disclosed 2018-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,138,274 |
Ending reported balance
After 2018-04-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-03 · Conversion · Acquired 1,110,932 · Balance 1,110,932 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Row 2 · 2018-04-03 · Conversion · Acquired 27,342 · Balance 1,138,274 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-03 · Conversion · Disposed 1,744,310 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-04-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-04-03 · Conversion · Disposed 42,931 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Denali Therapeutics Inc.
Report date December 12, 2017 · Filed December 14, 2017
Section 16 reporting ended · disclosed 2017-12-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,914,833 |
Ending reported balance
After 2017-12-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-12-12 · Conversion · Acquired 1,397,326 · Balance 1,814,208 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Row 2 · 2017-12-12 · Conversion · Acquired 28,750 · Balance 1,842,958 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Row 3 · 2017-12-12 · Conversion · Acquired 71,875 · Balance 1,914,833 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectAsia Ventures III L.P. | 1,383,774 |
Reported balance
After 2017-12-12 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2017-12-12 · Conversion · Acquired 1,065,616 · Balance 1,383,774 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectAsia Ventures III L.P. | 1,405,716 |
Reported balance
After 2017-12-12 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2017-12-12 · Conversion · Acquired 21,942 · Balance 1,405,716 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectAsia Ventures III L.P. | 1,460,570 |
Reported balance
After 2017-12-12 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2017-12-12 · Conversion · Acquired 54,854 · Balance 1,460,570 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectJapan Ventures I L.P. | 380,597 |
Reported balance
After 2017-12-12 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2017-12-12 · Conversion · Acquired 293,204 · Balance 380,597 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectJapan Ventures I L.P. | 386,624 |
Reported balance
After 2017-12-12 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2017-12-12 · Conversion · Acquired 6,027 · Balance 386,624 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectJapan Ventures I L.P. | 401,692 |
Reported balance
After 2017-12-12 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2017-12-12 · Conversion · Acquired 15,068 · Balance 401,692 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectFIL Capital Investments (Mauritius) II Limited | 379,427 |
Reported balance
After 2017-12-12 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2017-12-12 · Conversion · Acquired 292,303 · Balance 379,427 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectFIL Capital Investments (Mauritius) II Limited | 385,435 |
Reported balance
After 2017-12-12 transaction · row 11
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 11 · 2017-12-12 · Conversion · Acquired 6,008 · Balance 385,435 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectFIL Capital Investments (Mauritius) II Limited | 400,456 |
Reported balance
After 2017-12-12 transaction · row 12
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 12 · 2017-12-12 · Conversion · Acquired 15,021 · Balance 400,456 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectAsia Partners III L.P. | 4,876 |
Reported balance
After 2017-12-12 transaction · row 13
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 13 · 2017-12-12 · Conversion · Acquired 3,755 · Balance 4,876 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectAsia Partners III L.P. | 4,953 |
Reported balance
After 2017-12-12 transaction · row 14
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 14 · 2017-12-12 · Conversion · Acquired 77 · Balance 4,953 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectAsia Partners III L.P. | 5,146 |
Reported balance
After 2017-12-12 transaction · row 15
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 15 · 2017-12-12 · Conversion · Acquired 193 · Balance 5,146 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectJapan Partners I L.P. | 859 |
Reported balance
After 2017-12-12 transaction · row 16
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 16 · 2017-12-12 · Conversion · Acquired 662 · Balance 859 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectJapan Partners I L.P. | 872 |
Reported balance
After 2017-12-12 transaction · row 17
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 17 · 2017-12-12 · Conversion · Acquired 13 · Balance 872 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectJapan Partners I L.P. | 906 |
Reported balance
After 2017-12-12 transaction · row 18
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 18 · 2017-12-12 · Conversion · Acquired 34 · Balance 906 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectIndia Partners II L.P. | 1,308 |
Reported balance
After 2017-12-12 transaction · row 19
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 19 · 2017-12-12 · Conversion · Acquired 1,008 · Balance 1,308 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectIndia Partners II L.P. | 1,328 |
Reported balance
After 2017-12-12 transaction · row 20
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 20 · 2017-12-12 · Conversion · Acquired 20 · Balance 1,328 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectIndia Partners II L.P. | 1,379 |
Reported balance
After 2017-12-12 transaction · row 21
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 21 · 2017-12-12 · Conversion · Acquired 51 · Balance 1,379 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-12 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2017-12-12 · Conversion · Disposed 1,397,326 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectAsia Ventures III L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2017-12-12 · Conversion · Disposed 1,065,616 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectJapan Ventures I L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2017-12-12 · Conversion · Disposed 293,204 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectFIL Capital Investments (Mauritius) II Limited | 0 |
Reported balance
After 2017-12-12 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2017-12-12 · Conversion · Disposed 292,303 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectAsia Partners III L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2017-12-12 · Conversion · Disposed 3,755 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectJapan Partners I L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2017-12-12 · Conversion · Disposed 662 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectIndia Partners II L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2017-12-12 · Conversion · Disposed 1,008 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-12 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2017-12-12 · Conversion · Disposed 28,750 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectAsia Ventures III L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · 2017-12-12 · Conversion · Disposed 21,942 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectJapan Ventures I L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · 2017-12-12 · Conversion · Disposed 6,027 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectFIL Capital Investments (Mauritius) II Limited | 0 |
Reported balance
After 2017-12-12 transaction · row 32
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 32 · 2017-12-12 · Conversion · Disposed 6,008 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectAsia Partners III L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 33
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 33 · 2017-12-12 · Conversion · Disposed 77 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectJapan Partners I L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 34
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 34 · 2017-12-12 · Conversion · Disposed 13 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectIndia Partners II L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 35
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 35 · 2017-12-12 · Conversion · Disposed 20 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-12 transaction · row 36
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 36 · 2017-12-12 · Conversion · Disposed 71,875 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectAsia Ventures III L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 37
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 37 · 2017-12-12 · Conversion · Disposed 54,854 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectJapan Ventures I L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 38
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 38 · 2017-12-12 · Conversion · Disposed 15,068 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectFIL Capital Investments (Mauritius) II Limited | 0 |
Reported balance
After 2017-12-12 transaction · row 39
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 39 · 2017-12-12 · Conversion · Disposed 15,021 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectAsia Partners III L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 40
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 40 · 2017-12-12 · Conversion · Disposed 193 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectJapan Partners I L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 41
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 41 · 2017-12-12 · Conversion · Disposed 34 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectIndia Partners II L.P. | 0 |
Reported balance
After 2017-12-12 transaction · row 42
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 42 · 2017-12-12 · Conversion · Disposed 51 · Balance 0 F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock.
Structure Therapeutics Inc.
Report date February 07, 2023 · Filed February 09, 2023
Section 16 reporting ended · disclosed 2023-02-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectEight Roads Investments | 4,013,678 |
Reported balance
After 2023-02-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-02-07 · Conversion · Acquired 4,013,678 · Balance 4,013,678 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectEight Roads Investments | 4,634,177 |
Reported balance
After 2023-02-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-02-07 · Conversion · Acquired 620,499 · Balance 4,634,177 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectEight Roads Investments | 5,087,044 |
Reported balance
After 2023-02-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-02-07 · Conversion · Acquired 452,867 · Balance 5,087,044 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectEight Roads Investments | 5,266,286 |
Reported balance
After 2023-02-07 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2023-02-07 · Conversion · Acquired 179,242 · Balance 5,266,286 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectERVC Healthcare Advisors IV, LP | 71,636 |
Reported balance
After 2023-02-07 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2023-02-07 · Conversion · Acquired 71,636 · Balance 71,636 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectERVC Healthcare Advisors IV, LP | 81,790 |
Reported balance
After 2023-02-07 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2023-02-07 · Conversion · Acquired 10,154 · Balance 81,790 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectERVC Healthcare Advisors IV, LP | 89,201 |
Reported balance
After 2023-02-07 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2023-02-07 · Conversion · Acquired 7,411 · Balance 89,201 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectERVC Healthcare V, LP | 494,035 |
Reported balance
After 2023-02-07 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2023-02-07 · Conversion · Acquired 494,035 · Balance 494,035 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectERVC Healthcare IV, LP | 624,239 |
Reported balance
After 2023-02-07 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2023-02-07 · Conversion · Acquired 624,239 · Balance 624,239 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series A Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectEight Roads Investments | 0 |
Reported balance
After 2023-02-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-02-07 · Conversion · Disposed 4,013,678 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series A+ Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectEight Roads Investments | 0 |
Reported balance
After 2023-02-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-02-07 · Conversion · Disposed 620,499 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series B Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectEight Roads Investments | 0 |
Reported balance
After 2023-02-07 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-02-07 · Conversion · Disposed 452,867 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series B-1 Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectEight Roads Investments | 0 |
Reported balance
After 2023-02-07 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-02-07 · Conversion · Disposed 179,242 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series A Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectERVC Healthcare Advisors IV, LP | 0 |
Reported balance
After 2023-02-07 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-02-07 · Conversion · Disposed 71,636 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series A+ Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectERVC Healthcare Advisors IV, LP | 0 |
Reported balance
After 2023-02-07 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-02-07 · Conversion · Disposed 10,154 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series B Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectERVC Healthcare Advisors IV, LP | 0 |
Reported balance
After 2023-02-07 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-02-07 · Conversion · Disposed 7,411 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series B-1 Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectERVC Healthcare V, LP | 0 |
Reported balance
After 2023-02-07 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2023-02-07 · Conversion · Disposed 494,035 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| Series A Convertible Preferred SharesSEC Table II · derivative / convertible security | IndirectERVC Healthcare IV, LP | 0 |
Reported balance
After 2023-02-07 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-02-07 · Conversion · Disposed 624,239 · Balance 0 F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.
Surface Oncology, Inc.
Report date April 23, 2018 · Filed April 25, 2018
Section 16 reporting ended · disclosed 2018-04-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 886,716 |
Reported balance
After 2018-04-23 transaction · row 1
1 source rowRow 1 · 2018-04-23 · Conversion · Acquired 886,716 · Balance 886,716 F1: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-04-23 · Conversion · Disposed 1,950,777 · Balance 0 F1: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock.
Xilio Therapeutics, Inc.
Report date October 26, 2021 · Filed October 28, 2021
Section 16 reporting ended · disclosed 2021-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectEight Roads Investments | 218,705 |
Reported balance
After 2021-10-26 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-10-26 · Conversion · Acquired 218,705 · Balance 218,705 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectEight Roads Investments | 0 |
Reported balance
After 2021-10-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-26 · Conversion · Disposed 2,077,698 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2024 Filed Sep 18, 2024 15:54 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | ConversionSeries C Preferred Stock · Derivative | 352,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107661 · ownership.xml · derivative · entry 6 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 352,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 15:54 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | ConversionSeries B Preferred Stock · Derivative | 606,885 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107661 · ownership.xml · derivative · entry 5 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 606,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 15:54 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | ConversionSeries Seed Preferred Stock · Derivative | 54,092 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107661 · ownership.xml · derivative · entry 4 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 54,092 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 15:54 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | ConversionCommon Stock | 352,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107661 · ownership.xml · nonDerivative · entry 3 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P. Disclosed balance after: 1,013,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 15:54 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | ConversionCommon Stock | 606,885 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107661 · ownership.xml · nonDerivative · entry 2 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P. Disclosed balance after: 660,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 15:54 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | ConversionCommon Stock | 54,092 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107661 · ownership.xml · nonDerivative · entry 1 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P. Disclosed balance after: 54,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries A Convertible Preferred Shares · Derivative | 624,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 18 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare IV, LP Disclosed balance after: 0 Underlying: Ordinary Shares · 624,239 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries B-1 Convertible Preferred Shares · Derivative | 494,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 17 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare V, LP Disclosed balance after: 0 Underlying: Ordinary Shares · 494,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries B Convertible Preferred Shares · Derivative | 7,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 16 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare Advisors IV, LP Disclosed balance after: 0 Underlying: Ordinary Shares · 7,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries A+ Convertible Preferred Shares · Derivative | 10,154 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 15 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare Advisors IV, LP Disclosed balance after: 0 Underlying: Ordinary Shares · 10,154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries A Convertible Preferred Shares · Derivative | 71,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 14 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare Advisors IV, LP Disclosed balance after: 0 Underlying: Ordinary Shares · 71,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries B-1 Convertible Preferred Shares · Derivative | 179,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 13 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 0 Underlying: Ordinary Shares · 179,242 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries B Convertible Preferred Shares · Derivative | 452,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 12 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 0 Underlying: Ordinary Shares · 452,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries A+ Convertible Preferred Shares · Derivative | 620,499 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 11 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 0 Underlying: Ordinary Shares · 620,499 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries A Convertible Preferred Shares · Derivative | 4,013,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · derivative · entry 10 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 0 Underlying: Ordinary Shares · 4,013,678 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 624,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 9 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare IV, LP Disclosed balance after: 624,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 494,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 8 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare V, LP Disclosed balance after: 494,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 7,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 7 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare Advisors IV, LP Disclosed balance after: 89,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 10,154 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 6 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare Advisors IV, LP Disclosed balance after: 81,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 71,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 5 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · ERVC Healthcare Advisors IV, LP Disclosed balance after: 71,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 179,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 4 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 5,266,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 452,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 3 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 5,087,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 620,499 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 2 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 4,634,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 19:04 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 4,013,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-23-000054 · primary_doc.xml · nonDerivative · entry 1 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 4,013,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 19:57 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries B Preferred Stock · Derivative | 2,077,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-21-000078 · primary_doc.xml · derivative · entry 2 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 0 Underlying: Common Stock · 218,705 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. F1 · price: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. F1 · derivative.exercise_date: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. F1 · derivative.expiration_date: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 19:57 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 218,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-21-000078 · primary_doc.xml · nonDerivative · entry 1 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Eight Roads Investments Disclosed balance after: 218,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 19:56 UTC | Surface Oncology, Inc. SURF · Entity 109857 | ConversionSeries A Preferred Stock · Derivative | 1,950,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000023 · primary_doc.xml · derivative · entry 2 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 886,716 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 19:56 UTC | Surface Oncology, Inc. SURF · Entity 109857 | ConversionCommon Stock | 886,716 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000023 · primary_doc.xml · nonDerivative · entry 1 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | ConversionSeries B Preferred Stock · Derivative | 42,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · derivative · entry 4 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,342 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | ConversionSeries A Preferred Stock · Derivative | 1,744,310 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · derivative · entry 3 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,110,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.exercise_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. F1 · derivative.expiration_date: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | ConversionCommon Stock | 27,342 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · nonDerivative · entry 2 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:28 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | ConversionCommon Stock | 1,110,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-18-000018 · primary_doc.xml · nonDerivative · entry 1 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 51 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 42 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · India Partners II L.P. Disclosed balance after: 0 Underlying: Common Stock · 51 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 34 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 41 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Japan Partners I L.P. Disclosed balance after: 0 Underlying: Common Stock · 34 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 193 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 40 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Asia Partners III L.P. Disclosed balance after: 0 Underlying: Common Stock · 193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 15,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 39 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · FIL Capital Investments (Mauritius) II Limited Disclosed balance after: 0 Underlying: Common Stock · 15,021 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 15,068 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 38 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Japan Ventures I L.P. Disclosed balance after: 0 Underlying: Common Stock · 15,068 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 54,854 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 37 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Asia Ventures III L.P. Disclosed balance after: 0 Underlying: Common Stock · 54,854 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 71,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 36 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 20 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 35 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · India Partners II L.P. Disclosed balance after: 0 Underlying: Common Stock · 20 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 13 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 34 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Japan Partners I L.P. Disclosed balance after: 0 Underlying: Common Stock · 13 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 77 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 33 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Asia Partners III L.P. Disclosed balance after: 0 Underlying: Common Stock · 77 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 6,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 32 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · FIL Capital Investments (Mauritius) II Limited Disclosed balance after: 0 Underlying: Common Stock · 6,008 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 6,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 31 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Japan Ventures I L.P. Disclosed balance after: 0 Underlying: Common Stock · 6,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 21,942 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 30 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Asia Ventures III L.P. Disclosed balance after: 0 Underlying: Common Stock · 21,942 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 28,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 29 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 1,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 28 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · India Partners II L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,008 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 662 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 27 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Japan Partners I L.P. Disclosed balance after: 0 Underlying: Common Stock · 662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 3,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 26 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Asia Partners III L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,755 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 20:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 292,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000318989-17-000042 · primary_doc.xml · derivative · entry 25 FIL Ltd · CIK 0000318989 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · FIL Capital Investments (Mauritius) II Limited Disclosed balance after: 0 Underlying: Common Stock · 292,303 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · price: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.exercise_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. F1 · derivative.expiration_date: On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.